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The renin-angiotensin-aldosterone system is one of the major
hormonal systems involved in the long-term regulation of blood
pressure. The release of renin is the rate limiting step in the
activation of this system. As a result, it is important to
understand the factors involved in the regulation of renin
release to extend our knowledge of the role of this system in
cardiovascular regulation. Extensive research has revealed that
renin release may be affected by many local and circulating
factors. Rather than review this vast literature, the reader is
directed to several recent reviews of this topic [1—5]. This
review focuses on the regulation of renin release by local
factors that are formed by the endothelial cells of blood vessels
and forwards the hypothesis that endothelial factors are impor-
tant in the control of renin release.
Renin is synthesized and released from the juxtaglomerular
cells [1, 5]. These cells are modified smooth muscle cells and
are located in the media of the afferent arteriole. The endothe-
hal cells which line the lumen of the afferent arteriole are in
close anatomical proximity to the juxtaglomerular cells and may
release local hormones which alter juxtaglomerular cell func-
tion. Specifically, in recent years, it has become apparent that
endothelial cells release a number of vasoactive hormones,
growth factors and other soluble mediators which may affect
juxtaglomerular cells and renin release [6, 7]. Some of these
factors include eicosanoids such as PG!2 and PGE2, endothehial
derived relaxant factors (EDRF) which may include nitric
oxide, endothelial-derived constrictor factors including endo-
thelin, endothelial-derived growth factor, procoagulant factors,
tissue plasminogen activator and plasminogen activator inhibi-
tor. Additionally, endothelial cells form a barrier between the
blood and the renin secreting cells so circulating hormones must
first interact with the endothelial cells before reaching the
juxtaglomerular cells. This raises the possibility that the action
of circulating hormones on renin release may be mediated by a
direct action on the juxtaglomerular cell or through stimulation
of an endothelial factor then affects renin release. Furthermore,
several endothelial hormones as PG!2 and EDRF are released in
response to stretch or shear stress [8, 9]. These hormones may
function as the chemical mediators of the changes in renin
release caused by these mechanical forces. Thus, the available
information suggests that the endothelium may play a pivotal
role in the regulation of renin release. Several of the endothe-
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hal-derived hormones with effects on renin are discussed in
sequence below.
Effect of endothelial cell-derived hormones on renin release
Eicosanoids: Cyclooxygenase products
There is considerable evidence that metabolites of arachi-
donic acid, and prostaglandins in particular, are involved in the
regulation of renin release [2, 5]. If the renal synthesis of
prostaglandins is inhibited with cyclooxygenase inhibitors such
as indomethacin or meclofenamate, basal renin release and
some forms of stimulated renin release are inhibited [10—161. Of
particular interest, indomethacin inhibits baroreceptor-medi-
ated renin release, suggesting that prostaglandins function as a
chemical mediator for the mechanical changes that occur in the
afferent arteriole with alterations in perfusion pressure, blood
flow and wall tension [10, 11]. Less clear is the involvement of
prostaglandins in sympathetically-mediated renin release. Some
investigators have reported that indomethacin or meclofena-
mate block the renin released by f3-adrenergic agonist or
sympathetic activation [12, 13] while other researchers find no
effect [14, 151. This discrepancy may be explained by the ability
of prostaglandins to potentiate sympathetically-mediated renin
release 116]. Thus, in experimental conditions where the syn-
thesis of prostaglandins is high, cyclooxygenase inhibitors
reduce sympathetically-mediated renin release whereas the
inhibitors are without effect in inhibiting renin if prostaglandin
synthesis is low. Further support for a role of eicosanoids in
renin release is provided by studies with arachidonic acid.
Infusion of arachidonic acid in vivo or its addition to renal
cortical slices in vitro stimulates the release of renin [17—20].
Indomethacin inhibits this stimulation by arachidonic acid.
These data indicate that a prostaglandin(s) formed by the renal
cortex stimulates the release of renin.
Moncada and coworkers [21] were the first to describe that
blood vessels synthesize PGI2, a vasodilator and inhibitor of
platelet aggregation. Needheman et al [22] have reported that
PG!2 and PGE2 were the major prostaglandins released from the
isolated perfused kidney. Subsequent studies indicated that
these prostaglandins are of vascular origin [23]. Renal arteries
convert arachidonic acid predominately to PG!2 and to a lesser
extent to PGE2 [24]. The synthesis of PG!2 is greatly reduced
when the endothelium was removed. Thus, the vascular endo-
thelium is the likely major site of PG!2 synthesis. Endothelial
cells, cultured from a variety of vascular beds, synthesize PG!2
as their major cyclooxygenase metabolite of arachidonic acid
[25—28]. Furthermore, the release of PGI2 from endothehial cells
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is stimulated by a variety of hormones including bradykinin,
histamine and angiotensin as well as mechanical disruption and
shear stress.
Intrarenal infusions of PG!2 or PGE2 increase renal blood
flow, urinary sodium excretion and the release of renin without
altering the systemic blood pressure [29—311. Similar increases
in renal blood flow and renin release have been reported when
these prostanoids are infused into dogs with nonfiltering kid-
neys [30, 31]. Thus, these substances stimulate renin release by
activation of the intrarenal baroreceptor and/or a direct action
on the juxtaglomerular cells. To discriminate between these two
mechanisms, studies were conducted in vitro in renal cortical
slices. PGI2, but not PGE2, stimulated the release of renin from
renal slices and isolated glomeruli [19, 20, 32]. Thus, PG!2
appears to release renin by a direct action on the juxtaglomer-
ular cell while PGE2 releases renin by an indirect action,
probably mediated by the intrarenal baroreceptor [30]. Addi-
tionally, the stimulation of renin release by arachidonic acid
was associated with the release of PG!2 and PGE2 [33]. Indo-
methacin inhibited the release of renin and both prostaglandins.
In contrast, 9,ll-Azoprosta-5,l3 dinoic acid inhibited the syn-
thesis of PGI2 by renal slices without altering the synthesis of
PGE2, and inhibited both basal- and arachidonic acid-stimu-
lated renin release [33]. These data strongly suggest that PG!2 is
the cyclooxygenase metabolite that mediates renin release.
In renal cortical membranes, PG!2 stimulates adenylate cy-
clase activity [34]. It also promotes the accumulation of cyclic
AMP in renal cortical slices which is associated with the release
of renin [16, 35]. The adenylate cyclase inhibitor, 2',S'-dideoxy-
adenosine, has no effect on basal cyclic AMP formation or renin
release but inhibits the ability of PG!2 to increase cyclic AMP
accumulation and renin release. These data suggest that PG!2
promotes the release of renin through a cyclic AMP mechanism
analogous to the release of renin by /3-adrenergic agonists.
Eicosanoids: Lipoxygenase products
In addition to the cyclooxygenase pathway, arachidonic acid
may be metabolized by the lipoxygenase pathway in the renal
cortex. Jim and coworkers [36] have described the presence of
lipoxygenase activity in rat renal glomeruli and the synthesis of
12-hydroxyeicosatetraenoic acid (l2-HETE). Glomerular epi-
thelial cells were thought to be the source of the HETE. Human
glomeruli synthesized 12- and 15-HETE [37]. Additionally,
isolated glomeruli synthesize LTB4 and its synthesis increases
in glomerulonephritis [38, 39]. This indicates that glomeruli
must contain the 5-lipoxygenase and synthesize 5-HPETE. The
5-HPETE is metabolized to LTA4 by leukotriene synthetase
and converted to LTB4 by a LTA hydrolase [40]. LTA4 is
apparently not conjugated to glutathione in glomeruli as there is
no evidence of LTC4 synthesis [41]. Resident macrophages
appear to be the source of this eicosanoid [39]. !n separate
studies we found that renal cortical slices convert arachidonic
acid to 12- and 15-HETE [42, 43]. While renal vessels and renal
vascular endothelial cells have not been studied, these same
synthetic pathways for arachidonic acid have been described
for blood vessels and endothelial cells from other vascular beds
[27, 28, 44—46]. Human umbilical vein endothelial cells, for
example, converted arachidonic acid to mainly 12-, 15- and
1 1-HETE, and a lesser amount of 5-HETE [28, 44]. While
l2-HETE was a product of a l2-lipoxygenase, 15- and I 1-HETE
appeared to arise from cyclooxygenase in these cells [28]. This
was, however, not a consistent finding [44]. Endothelial cells
from the bovine coronary artery, bovine aorta and human
pulmonary artery also synthesize these HETEs [27, 45, 46].
However, in cells from these vessels, the HETEs appear to
arise from the action of lipoxygenases. Endothelial cells do not
synthesize leukotrienes from arachidonic acid [47, 48]. How-
ever, if LTA4 is provided to the endothelial cell by a neutrophil
or possibly a macrophage, it is converted to LTC4 and LTD4
[47, 48]. These studies indicate that renal tissue and endothelial
cells synthesize HETEs and HPETEs and that in certain
pathological conditions may synthesize leukotrienes.
Studies are now emerging which suggest that the HETEs,
HPETEs, and LTs may be active in the regulation of renin
release. For example, Antonipollai et a! [49] have recently
documented the fact that 12-HPETE (10 M) and 12-HETE
(10—8 M) inhibit basal renin secretion in rat cortical slices. In
addition, l5-HPETE (lO_6 M) and 15-HETE (106 M) were also
inhibitory to renin release [49]. Of interest is the fact that LTB4,
LTC4, LTD4 and 5-HPETE (all at l0 M) did not alter basal
renin release. These results suggested that relatively low con-
centrations of l2-HPETE and 12-HETE could exert a major
(about 30% inhibition) inhibitory action on renin release. In
subsequent studies, angiotensin !! was found to stimulate
12-HETE formation in superficial rat renal cortical slices and in
isolated juxtaglomerular-like cells [50]. When the formation of
12-HETE was blunted using lipoxygenase synthesis inhibitors
(BW775c, l0 M and baicalein, l06 M), significant increases in
renin release (to 131% 4% of control values) were noted.
Most notably, inhibition of renin release by angiotensin II was
not as apparent. Although these studies did not resolve the
mechanisms involved in these effects, they do suggest that
lipoxygenase products may serve as important intermediaries in
the feedback response of angiotensin II on renin secretion.
In contrast to the findings of Antonipollai et al [50], our
laboratory did not document significant renin release inhibition
with 15-HETE or related products. However, we have shown
that LTD4 may increase renin release in rat cortical slices [51].
The local effects of LTD4 are likely multiple: (1) inhibition of
cGMP formation, an effect which is known to occur as a result
of LTD4 action in the kidney [52]; (2) vasoconstriction [53],
which could promote renin secretion; and (3) an increase in
cytoslic calcium concentration [54], which would tend to reduce
renin secretion if it occurred in renin-producing cells. LTD4
(and the other LTs) deserve further study because they may
become important in the renin release process under patholog-
ical circumstances, such as in glomerulonephritis or tubuloint-
erstitial nephritis.
Eicosanoids: Cytochrome P450 epoxy genase products
Capdevila and coworkers [55, 56] first described the metab-
olism of arachidonic acid to HETEs, epoxyeicosatrienoic acids
(EETs) and the hydrolysis products of the EETs, the dihydroxy-
eicosatrienoic acids (DHETs) by liver cytochrome P450. Subse-
quently, they extended this work to the kidney and demon-
strated that purified porcine renal cytochrome P450 also
metabolized arachidonic acid [57]. Oliw et al [58] identified the
major metabolites of rabbit renal cortical microsomes as 14,15-
DHET, 11, 12-DHET, 19-HETE and 20-HETE. Extracts of the
kidney and human urine were found to contain 14,15- and
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8,9-EET; however, these products are probably derived from
cytochrome P450 present in the tubular cells [59, 60]. The 14,15-,
11,12-, 8,9- and 5,6-EET were also synthesized from arachi-
donic acid by rat renal cortical slices [43]. Cytochrome P4.
activity has also been identified in blood vessels and localized to
the intima of the vessel [61]. Subsequently, endothelial cells
have been shown to synthesize 14,15-, 11,12- 8,9- and 5,6-EET
from arachidonic acid, which further substantiates the presence
of this enzyme in endothelial cells [27, 28]. Thus, these metab-
olites may be of tubular or endothelial origin in the kidney.
The 5,6-EET is a vasodilator [62, 631 and affects sodium and
potassium transport in rabbit cortical collecting tubule [64].
Further, the 14, lS-DHET has been shown to inhibit vasopressin
hydraulic conductivity in cortical collecting tubules, and a
P450-linked enzyme has been shown to inhibit vasopressin-
stimulated cAMP in the LLC-PK1 epithelial cell line [651. A
recent study also tested the ability of the four EETs to alter
basal and isoproterenol-stimulated renin release in cortical
slices [431. None of the EETs altered basal renin secretion;
however, 14,15-EET (10—6 M) significantly inhibited renin se-
cretion stimulated by isoproterenol. Only about 10% of the
14,15-EEl was metabolized to the 14,15-DHET. The four
EETs failed to affect tissue cGMP or cAMP formation. Thus,
the mechanism of the renin inhibition with 14,15-EEl is un-
clear; however, it may conceivably be related to a change in
intracellular calcium. The exact role of EETs as a potential
regulator of renin secretion will have to await future studies.
The fact that both endothelial cells and the pars recta of the
proximal tubule synthesize EETs certainly makes the possibil-
ity intriguing that EETs may play a role in affecting renin
secretion locally.
Endothelial-derived relaxing factor (EDRF)
Furchgott and Zawadzki [66] were the first to report that
acetylcholine caused relaxation of the rabbit aorta if the endo-
thelium was present. However, if the endothelium was re-
moved, acetyicholine caused contraction. The authors sug-
gested that the endothelium released a dilator substance which
they called endothelium-derived relaxant factor (EDRF). These
findings have been confirmed by a number of investigators,
extended to other vasodilators, and extended to other blood
vessels [67, 68]. Subsequently, it was shown that EDRF could
be transferred from a donor blood vessel with an endothelium
or from cultured endothelial cells to cause vasodilation in a test
vessel without an endothelium [69—73]. Using this method,
EDRF was found to be unstable with a t112 of 6 to 20 seconds;
however, its stability was increased by the addition of super-
oxide desmutase [69—731. Endothelial-dependent vasodilation
was blocked by oxyhemoglobin which binds EDRF and by
methylene blue which inhibits guanylate cyclase [74—761. Addi-
tionally, EDRF stimulated guanylate cyclase and increased the
vascular synthesis of cyclic GMP. Thus, it was proposed that
cyclic GMP mediated the vasodilation by EDRF.
The chemical identity of EDRF is unknown. It was originally
thought to be a lipoxygenase metabolite of arachidonic acid
[66]. However, recent studies have suggested that EDRF may
be nitric oxide and arginine may be its precursor [77, 78]. This
conclusion was based on similar properties of the two com-
pounds: both cause vasodilation, stimulate guanylate cyclase,
inhibit platelet aggregation, have short t112's and bind to hemo-
globin. However, this has also been questioned since EDRF
and nitric oxide differ in some of their other chemical and
pharmacological properties [79, 80].
With regard to renin release, Vidal, Romero and Vanhoutte
[811 reported that the perfusate from a carotid artery with an
intact endothelium failed to affect the release of renin from renal
cortical slices. However, if acetylcholine was added to the
perfusate, renin release was suppressed. Acetylcholine added
directly to the kidney slices had no effect on renin release. The
addition of oxyhemoglobin to the perfu sate had no direct effect
on renin release but blocked the inhibition by acetylcholine. It
was concluded that acetyicholine released a factor with the
properties of EDRF that inhibited renin release. While these
data are preliminary, other lines of evidence would indirectly
support this contention. For example, other agents which
increase cyclic GMP accumulation as atriopeptins, sodium
nitroprusside and 8-bromo-cyclic GMP also inhibit the release
of renin [82]. Furthermore, inhibition of guanylate cyclase with
methylene blue blocks the inhibition of renin release and the
increase in cyclic GMP by atriopeptins and sodium nitroprus-
side. These findings suggest that cyclic GMP functions as an
intracellular second messenger to inhibit the release of renin.
While the effect of methylene blue on the effect of EDRF has
not been tested or cyclic GMP measured, it is likely that an
agent like EDRF which activates guanylate cyclase will inhibit
the release of renin. Further studies will be required to clarify
the role of EDRF and its mechanism of action.
Endothelin
Using techniques similar to those of Furchgott and Zawadzki
[66], Hickey and coworkers [83] described the release of a
constrictor peptide by the vascular endothelium. This was
subsequently confirmed by several workers [841. In a remark-
ably comprehensive article, Yanagisawa and coworkers [85]
described the isolation, purification, sequencing, cloning, bio-
logical activity and regulation of synthesis of this vasoconstric-
tor peptide. This 21-amino acid cyclized peptide was called
endothelin. Other members of this family have subsequently
been identified. As an endothelial peptide, it is not surprising
that the kidney contains endothelin [86]. It is present in both the
cortex and medulla but is in highest concentration in the
medulla. In addition, the kidney contains receptors for endo-
thelin [87, 88]. The vasoconstrictive effects of endothelin on
vascular smooth muscle are, in large part, dependent upon an
increase in intracellular calcium [85, 89]. This increase in
intracellular calcium in turn apparently results from mobiliza-
tion of calcium from intracellular pools rather than by activation
of calcium channels [89].
The effects of endothelin on renin secretion depend upon the
model studied. Miller, Redfield and Burnett [90] have infused
endothelin (50 nglkg/min) systemically into anesthetized dogs
and observed a sharp increase in plasma renin activity (PRA) to
approximately twice the baseline value. During this infusion,
mean blood pressure increased from 98 7 to 134 6 mm Hg,
renal blood flow declined from 267 33 to 63 20 mI/mm and
glomerular filtration rate decreased dramatically from 39 4 to
0.7 .2 ml/min. Clearly, the renal vasoconstrictive influence of
this dose of endothelin profoundly decreased renal hemody-
namics, activated the intrarenal baroreceptor and macula
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densa-mediated pathways to renin secretion, and increased
PRA.
Endothelin may also have local, intrarenal effects that are
important in the regulation of local renal hemodynamics and
renin release. Endothelin activates the formation of 1P3 and
increases mesangial cell contraction [91]. It also lowers Kfin in
vitro studies in rats at concentrations of 10 flM. Several studies
have noted inhibition of renin release with endothelin in vitro
[92—94]. These studies used cortical slices [92], superfused JG
cells [93], and isolated rat glomeruli [94]. In these studies [92,
94], the calcium channel blocker nifedipine or eliminating
calcium from the incubation media blunted the inhibition of
renin release by endothelin. Our results with endothelin in
superficial cortical slices and isolated JG cells suggest a similar
inhibition of renin release. The use of an intracellular calcium
buffering agent BAPTA blocked the ability of endothelin to
inhibit renin release [95]. Thus, there is a consensus regarding
in vitro effects of endothelin on renin release: renin inhibition
occurs, likely secondary to an increase in intracellular calcium.
When large systemic doses of endothelin are administered,
profound renal vasoconstriction supervenes and PRA in-
creases. Endothelin may have a regulatory role in local regula-
tion of renin secretion given its potent renin inhibitory effect.
Since angiotensin and vasopressin release endothelin from
endothelial cells [96], the possibility exists that endothelin
contributes to the inhibition of renin release by these peptides.
Role of the endothelium in renin release
The direct evidence indicating that renin release is dependent
on endothelial cell factors is limited. Beirwaltes [97] has inves-
tigated the role of the endothelium in the release of renin from
rat renal cortical slices. Acetylcholine, an endothelium depen-
dent vasodilator, has no effect on renin release when used alone
but potentiates PGE2-stimulated renin release. The potentiation
by acetylcholine was blocked by atropine. Nitroprusside, an-
other endothelium-independent vasodilator, failed to alter basal
or PGE2-stimulated renin release. If the endothelium is re-
moved by perfusing the kidney with hydrogen peroxide prior to
preparing the kidney slices, the potentiation by acetylcholine is
eliminated. These data suggest that an endothelial factor en-
hances the effect of PGE2. Unfortunately, other substances
which release renin were not tested in these experiments. Of the
known endothelial factors, endogenous PG!2 or PGE2 would be
likely mediators of this response; however, there were no
attempts to determine the identity or properties of this enhanc-
ing factor(s). As mentioned above, Vidal, Romero and Van-
houtte [81] superfused renal cortical slices with a solution that
either passed through a carotid artery with the endothelium
intact or via a steel cannula. Indomethacin was included in the
superfusion fluid to eliminate the influences of endogenous
prostaglandins. Acetyicholine did not alter renin release when
added to the slices via the steel cannula. Thus, it had no direct
effect on renin release. However, when acetyicholine was
added to the perfu sate of the carotid artery and then allowed to
superfuse the renal slices, renin release was reduced. Oxyhe-
moglobin, an inhibitor of EDRF, blocked the inhibition of renin
release by acetyicholine without altering basal renin release.
This indicated that the inhibitory factor was EDRF rather than
endothelin. Thus, a factor with the properties of EDRF was
released from a donor vessel and inhibited the release of renin
from renal cortical slices. Unfortunately, vessels without an
intact endothelium were not tested so there is no conclusive
evidence that the endothelium is the source of the inhibitory
factor. Since indomethacin was included in the perfusate, there
is no clear indication whether inhibition of renin release by
EDRF or stimulation by PG!2 predominates under usual cir-
cumstances.
Conclusions
Because of their close anatomical relationship, it is not
surprising that endothelial cells may influence the function of
juxtaglomerular cells to release renin. This ability is in accor-
dance with the known paracrine function of the endothelium.
This contention is supported by considerable evidence that
endothelium derived hormones may dramatically influence re-
nm release. Future studies need to determine the exact contri-
bution of these endothelial hormones or factors to the control of
renin release. Since both EDRF and PG!2 are released with
changes in shear stress or flow [8, 9], it will also be important to
clearly determine the role of these endothelial hormones in
baroreceptor-mediated renin release.
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